NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Waaree Energies: Mitigating Risks in the US Market

Overview

Emkay Global Financial's research report on Waaree Energies highlights the company's ability to navigate the recent imposition of preliminary Countervailing Duty (CVD) on solar PV imports from India, Indonesia, and Laos by the US Department of Commerce. This development has led to a sharp stock correction among Indian players.

Key Developments

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Waaree Energies' management has clarified that the company's US supplies are unlikely to be impacted by the CVD/ADD measures, as they source solar cells from countries with lower US duties, approximately 10%. The company has diversified its sourcing to countries outside of India and the affected nations, ensuring compliance with Free and Open Market Obligations (FEOC).

Capacity Expansion

Waaree Energies has ramped up its US supplies, with significant capacity expansions in Arizona and Texas. The company has acquired 1 GW of capacity in Arizona and is expanding its operations in Texas by 1.6 GW. This expansion is expected to take the company's total US capacity to approximately 4.2 GW by mid-CY26, sufficient to meet its current order book.

Outlook

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

With its diversified non-China sourcing, Waaree Energies is well-positioned in the US market, a key focus area for the company. Emkay Global Financial retains its estimates and reiterates a BUY rating with a target price of Rs 4260.

Investor Takeaway

Investors should consider Waaree Energies' diversified sourcing strategy and expanding US capabilities.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.